Trained as a chemical biologist and worked in biopharmaceutical industry for many years, I focus my research interests on the discovery and development of first-in-class therapies for unmet medical needs. These programs are of greater societal and economic impact compared to me-too therapies, although they are associated with higher risks. After working in both academia (Scripps Research) and industry (Regulus Therapeutics) leading drug discovery and development programs, I grew more interested in entrepreneurial activities. In April 2020, I co-founded PhenoTarget Biosciences, Inc. We have in-licensed small molecule therapeutic programs from Scripps Research that target novel mechanisms for the treatment of cancer, fibrosis, and ageing-related diseases. I obtained my master's degree in Analytical Chemistry from Nankai University in China and doctorate degree in Chemical Biology from University of Illinois at Chicago. I did postdoctoral research in Peter Schultz's lab at Scripps Research Institute. Following my academic career, I joint California Institute for Biomedical Research (CALIBR, now Scripps Research) leading drug discovery research in oncology, regenerative medicine and infectious diseases. I was Director of Research at Regulus Therapeutics working on developing oligonucleotide-based therapies before co-founding PhenoTarget.